TITLE

Topical Imiquimod: A Review of its Use in Genital Warts

AUTHOR(S)
Perry, C.M.; Lamb, H.M.
PUB. DATE
August 1999
SOURCE
Drugs;Aug1999, Vol. 58 Issue 2, p375
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream for application by the patient. It is the first agent of its class, the immune response modifiers, to be used in the treatment of genital warts. In immunocompetent patients with genital warts, imiquimod stimulates the production of interferon-α and various other cytokines, and has indirect antiviral activity. In randomised, double-blind, vehicle-controlled clinical trials, complete clearance of warts occurred in 37 to 50% of immunocompetent patients with genital warts treated with imiquimod 5% cream 3 times a week for up to 16 weeks; partial clearance of warts (defined as a reduction in wart area of ≥50%) was observed in 76% of recipients of imiquimod 5% cream. Rates of complete or partial clearance of warts were significantly higher in patients who applied imiquimod 5% cream 3 times a week than in recipients of imiquimod 1% or vehicle cream, each applied 3 times a week. A between-gender difference in clinical response to imiquimod 5% cream has been reported, with female patients experiencing higher rates of complete clearance of warts than males. Recurrence(s) of ≥1 wart occurred in 13 to 19% of immunocompetent patients in whom complete clearance of warts had been achieved with imiquimod 5% cream. Imiquimod 5% cream also shows some clearance of warts in immunosuppressed HIV-infected patients with genital warts. Preliminary results of a vehicle-controlled study showed that the rate of partial clearance of warts (defined as a reduction in baseline wart area of >50%) [38%] was significantly higher with imiquimod 5% cream than with vehicle cream; however, the rate of complete clearance was not significantly higher than with vehicle cream. Imiquimod 5% cream is generally well tolerated by immunocompetent and HIV-infected patients. Local skin reactions (mainly mild or moderate), including erythema, itching and burning, are the most commonly reported adverse events, occurring in ≤67% of patients applying imiquimod 5% cream 3 times a week. The incidence of adverse events is lower in patients applying the cream 3 times a week than with daily application. The incidence of systemic adverse events with imiquimod 5% cream (applied daily or 3 times a week) is similar to that of vehicle cream. The tolerability profile of imiquimod cream appears favourable compared with that of podophyllotoxin. Conclusion: Imiquimod 5% cream is a new therapeutic option for patients with genital warts. It produces clearance rates broadly similar to those of other treatment approaches and rates of wart recurrence compare favourably with those reported for established treatments. In contrast to most alternative treatment strategies, which are administered in the physician's office, imiquimod cream is a self-administered therapy for outpatient use.
ACCESSION #
9592868

 

Related Articles

  • Genital Wart Vaccine on Trial. Luntz, Stephen // Australasian Science;Aug2007, Vol. 28 Issue 7, p14 

    The article reports on the trial being conducted in Australia to see whether an adjusted version of the Gardasil vaccine for cervical cancer can eliminate genital warts for those who have already been infected. Professor Ian Frazer hopes that putting the virus-like particles capable of creating...

  • Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient. Gayed, S. L. // International Journal of STD & AIDS;May2002, Vol. 13 Issue 5, p349 

    Renal transplant recipients represent a patient subgroup for whom the effective treatment of genital warts poses a significant problem in genitourinary medicine. This case demonstrates the safe and effective treatment of resistant perianal warts in a male renal transplant recipient using imiquimod.

  • Imiquimod use in adolescents: off-label but effective. Greensill, A.; Yong, M.; Mahony, C. O' // International Journal of STD & AIDS;Apr2012, Vol. 23 Issue 4, p297 

    Genital warts are very common in the under-18 years old population, yet treatment with imiquimod is currently off-label. We looked at 50 cases of genital warts in patients aged under 18 years who had been treated with Imiquimod to see if this treatment was effective, and it was.

  • Warts and all.  // Good Health (Australia Edition);Oct2012, p61 

    The article offers tips from Dr. Shobhan Manoharan, director of Brisbane's Westside Dermatology in Queensland, on how to treat warts. Manoharan explains the cause of warts and how the disease can be transmitted as well as the need to treat warts which can be painful depending on where they are...

  • Using Imiquimod for Genital Warts in Female Patients. Cox, J. Thomas; Petry, Karl-Ulrich; Rylander, Eva; Roy, Michel // Journal of Women's Health (15409996);Apr2004, Vol. 13 Issue 3, p265 

    Genital warts (GW) are the manifestation of infection with specific types of human papillomavirus (HPV), one of the most common sexually transmitted viral infections in the world. Genital warts can be either raised (exophytic) or flat. Exophytic genital warts are most commonly secondary to...

  • Bumps in the night.  // Men's Health;Jun94, Vol. 9 Issue 5, p30 

    Discusses various aspects of genital warts. Symptoms and treatments.

  • What you should know about genital warts.  // American Family Physician;9/15/1995, Vol. 52 Issue 4, p1149 

    Focuses on genital warts. Definition; Sexual transmission of the disease; Diagnosis; Treatment modalities; Cryotherapy.

  • Genital warts still a mystery to too many Americans. Gannon, Kathi // Drug Topics;1/10/94, Vol. 138 Issue 1, p31 

    Reports on the results of the Candyloma Education Council's survey showing that many Americans do not know much about the subject of genital warts. Percentage who saw themselves at risk; Knowledge of the public on the subject; Knowledge of treatment procedures; Role of pharmacists in informing...

  • Confused about genital warts. Lever, Janet; Schwartz, Pepper // Glamour;June97, Vol. 95 Issue 6, p59 

    Responds to a reader asking about genital warts. External genital warts; Treatment options.

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics